Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Press Release/Announcement

Kadcyla (ado-trastuzumab emtansine): drug safety communication—potential medication errors resulting from name confusion.

Kadcyla (ado-trastuzumab emtansine): drug safety communication—potential medication errors resulting from name confusion. MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; May 6, 2013.

Save
Print
May 15, 2013
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; May 6, 2013.

This announcement describes the risk of medication mix-ups associated with the use of an incorrect nonproprietary name for a breast cancer drug.

Save
Print
Cite
Citation

Kadcyla (ado-trastuzumab emtansine): drug safety communication—potential medication errors resulting from name confusion. MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; May 6, 2013.